Chymotrypsin in Pregnancy
Chymotrypsin should be avoided during pregnancy unless absolutely necessary, as there is insufficient safety data to recommend its use. The FDA drug label explicitly states that pregnant women should "ask a healthcare professional before use," indicating lack of established safety 1.
Evidence Assessment
Available Safety Data
The evidence base for chymotrypsin use in pregnancy is extremely limited:
- FDA labeling provides only a precautionary warning requiring consultation with a healthcare professional before use in pregnancy, without specific safety data 1
- No pregnancy-specific guidelines exist from major medical societies (EULAR, ESC, ACR, or other authoritative bodies) addressing chymotrypsin use during pregnancy
- Research literature contains no human pregnancy safety studies for chymotrypsin
Clinical Context
The available evidence discusses chymotrypsin primarily in two contexts that are not relevant to pregnancy safety:
- Fertility treatment: One study used chymotrypsin/galactose to treat sperm-bound antibodies prior to intrauterine insemination 2, but this addresses male factor infertility treatment, not maternal drug exposure during pregnancy
- Animal sepsis models: Research on alpha-chymotrypsin's anti-inflammatory effects in rats 3 cannot be extrapolated to human pregnancy safety
Recommendation
Avoid chymotrypsin during pregnancy. Given the complete absence of human pregnancy safety data and the FDA's explicit warning requiring healthcare professional consultation, the risk-benefit analysis does not support its use.
If Use is Being Considered:
- First trimester: Absolutely avoid due to organogenesis period and complete lack of teratogenicity data
- Second/third trimester: Only consider if there is a compelling maternal indication with no safer alternatives available
- Document informed consent discussing the unknown fetal risks
- Consider alternative therapies with established pregnancy safety profiles for the underlying condition
Key Caveats:
The homeopathic formulation referenced in the FDA label 1 suggests extremely diluted preparations that may have negligible systemic exposure, but even for these formulations, the manufacturer recommends consulting a healthcare professional during pregnancy. This conservative approach reflects the absence of safety data rather than evidence of harm.
The fundamental principle remains: without adequate safety data demonstrating lack of harm to maternal-fetal outcomes (mortality, morbidity, quality of life), chymotrypsin cannot be recommended during pregnancy.